Preclinical evaluation and pilot clinical study of [(68)Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 15. Clin Nucl Med. 2025 Sep 1;50(9):e516-e522. doi: 10.1097/RLU.0000000000006039. Epub 2025 Jul 14. The Prognostic Value of Baseline 18 F-FDG PET/CT in Stage IV Non-Small Cell Lung Cancer Patients Receiving Osimertinib Treatment. Jiang ZP(1), Shan HM(1)(2), Zhu HY(3), Cheng Y(3), Lu KY(3), Fan W(2), Shao D(3). Author information: (1)Department of Nuclear Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology. (2)Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center. (3)Department of PET Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China. PURPOSE: This study aimed to evaluate the role of various metabolic parameters derived from baseline 18 F-FDG PET/CT in predicting the prognosis of stage IV non-small cell lung cancer (NSCLC) patients scheduled to receive osimertinib treatment. PATIENTS AND METHODS: A retrospective analysis was conducted on 177 NSCLC patients (98 males, 79 females; mean age 58.5 ± 11.0 y) who underwent osimertinib therapy and 18 F-FDG PET/CT scanning before treatment. Clinical and PET/CT parameters were assessed, including age, sex, smoking history, brain metastasis, bone metastasis, CEA level, SUVmax, SUVmean, SUVpeak, metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Receiver operating characteristic (ROC) curve analysis was used to calculate the optimal cutoff values for all parameters. Progression-free survival (PFS) was analyzed using log-rank tests, Kaplan-Meier curves, and Cox proportional hazard models to identify prognostic markers. RESULTS: The mean follow-up period was 15.24 ± 8.14 months. Univariate analysis revealed that SUVmax, SUVmean, MTV, and TLG were significantly associated with PFS, with cutoff values of 12.3, 8.57, 13.49 cm 3 , and 162.37, respectively. The hazard ratios were 1.776 ( P = 0.007), 2.155 ( P ＜0.001), 3.312 ( P < 0.001), and 3.370 ( P < 0.001), respectively. Multivariate survival analysis indicated that MTV was an independent prognostic factor for PFS (HR = 2.323; P = 0.012). CONCLUSIONS: Baseline PET/CT metabolic parameters before osimertinib treatment may help identify potential NSCLC patients who could derive clinical benefit, and baseline MTV of the primary tumor from 18 F-FDG PET/CT is a reliable prognostic indicator for PFS in stage IV NSCLC patients treated with osimertinib. Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/RLU.0000000000006039